Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Appl Thromb Hemost
Asıl Yazarlar: Sokol, Juraj, Nehaj, Frantisek, Ivankova, Jela, Mokan, Michal, Lisa, Lenka, Zolkova, Jana, Vadelova, Lubica, Mokan, Marian, Stasko, Jan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7573709/
https://ncbi.nlm.nih.gov/pubmed/33054412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620948585
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller